Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Prson Gautam, PhD
CONTACT
Lily Nahidi, PhD
CONTACT
Lead
Telix Pharmaceuticals (Innovations) Pty Limited
With
This is a randomized, open-label, multi-center 3 study evaluating the safety and efficacy of 177Lu-TLX250, a CAIX-targeting radioligand therapy, in adult participants with advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). The study consists of two parts: • Part 1 (Phase 2a - Dose Optimization): Participants will be randomized to receive one of two dosing regimens of 177Lu-TLX250. The objective of Part 1 is to determine the recommended Phase 3 dose (RP3D) for use in Part 2.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted